Company Presentation

Avrion Therapeutics, spin-off from the Swiss Federal Institute of Technology Lausanne (EPFL), develops innovative precision gene therapies for neurodegenerative disorders.
Our first development candidate, AVR-001, targets a form of amyotrophic lateral sclerosis (ALS) associated with pathogenic aggregates of Superoxide Dismutase 1 (SOD1). AVR-001 has been specifically engineered for dual targeting of the two key cell types involved in the pathology of ALS, neurons and astrocytes. This dual targeting allows to maximise treatment efficacy and safety, which we demonstrated in mouse models of ALS and non-human primate studies. AVR-001 is now ready for regulatory toxicology studies and clinical trials.